Kyle Brandon Williams

This study develops a gene-enhanced HSV therapy for MPNST by exploiting PRC2 loss and tumor-regulated ICP34.5 expression to improve viral efficacy.

The paper develops EXACT, a framework combining ex vivo drug screening with transcriptomic analysis to identify effective drug combinations for rare cancers, finding a MEK and HDAC inhibitor combination shows enhanced activity.

This study identifies 23 compounds that selectively kill NF1-deficient Schwann cells and shows their efficacy in vivo, with synergy when combined with Selumetinib.

This study shows that autophagy inhibition enhances MEK inhibitor effectiveness in NF1-mutated tumor cells, both in vitro and in a clinical trial.